Zealand Pharma at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Zealand Pharma brings 1 presentation to ObesityWeek 2026 in National Harbor, and exhibits at Booth 333, Suite 9. Its program addresses the role of amylin analogues in future obesity care.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Zealand Pharma Søborg, Denmark | ◇Bronze Sponsor |
Biotech developing peptide medicines for obesity and metabolic disease, including the amylin analogue petrelintide, partnered with Roche. | Booth Exhibiting at Booth 333, Suite 9 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sun Nov 15 11:45am–1:15pm Treating Obesity First: Exploring the Role of Amylin Analogues in the Future of Obesity Care Reviews trial data on amylin analogues, which act through a different hormone pathway than GLP-1, as single or combination obesity treatments. Interventional and clinical studiesNutrition, diet and food |
Find decision makers at Zealand Pharma
Tell us what you sell and we’ll find the people at Zealand Pharma most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction